Rheumatoid Arthritis Clinical Trials Rheumatoid Arthritis RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cohort Project of Patients With Inflammatory Rheumatism
Conditions: Rheumatoid Arthritis; Spondyloarthritis, Axial; Psoriatic Arthritis Interventions: Other: no intervention Sponsors: Centre Hospitalier Universitaire de Nice Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.
Conditions: Rheumatoid Arthritis (RA); Inflammatory Bowel Disease - IBD1 Interventions: Drug: ZL-82 12.5mg; Drug: ZL-82 25mg; Drug: ZL-82 50mg; Drug: ZL-82 100mg; Drug: ZL-82 200mg; Drug: ZL-82 300mg; Drug: ZL-82 450mg; Drug: ZL-82 600mg Sponsors: Chengdu Zenitar Biomedical Technology Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition:   Rheumatoid Arthritis Interventions:   Other: Treatment target DAS28CRP-LDA;   Other: Treatment target SDAI-remission Sponsor:   Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition:   Moderate to Severe Active Rheumatoid Arthritis Interventions:   Drug: HS628+MTX;   Drug: Actemra +MTX Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials